A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option

  title={A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option},
  author={Asa Peterson and Amy Bansal and Florence H. Hofman and Thomas C Chen and Gabriel Zada},
  journal={Journal of Neuro-Oncology},
Abstract The intranasal route for drug delivery is rapidly evolving as a viable means for treating selected central nervous system (CNS) conditions. We aimed to identify studies pertaining to the application of intranasal drug administration for the treatment of primary CNS tumors. A systematic literature review was conducted to identify all studies published in the English language pertaining to intranasal therapy for CNS neoplasms, and/or general mechanisms and pharmacokinetics regarding… 
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.
The usefulness of intranasal administration as a non- invasive and efficient means of delivering therapeutics to the brain to treat neurodegenerative diseases including Alzheimer's disease is confirmed.
Intranasal drug delivery: opportunities and toxicologic challenges during drug development
The anatomical, histological and physiological basis and currently approved drugs for administration via intranasal delivery, as well as for CNS indications, are described and summarized.
Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model
Although this study demonstrates feasibility and safety of intranasal drug administration, further agent-specific studies are necessary to optimize agent selection and dosing to achieve clinically-relevant CSF exposures.
Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression.
  • C. Andrade
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2015
The advantages and applications of INDD in neuropsychiatry are examined; examples of test, experimental, and approved INDD treatments are provided; and the potential of intranasal ketamine for the acute and maintenance therapy of refractory depression is focused on.
Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases
Advances in intranasal delivery to achieve direct nose-to-brain transport of anticancer agents and covalent modification of existing drugs to support enhanced penetration of the blood-brain barrier are reviewed.
Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma
Intranasal glioma therapy with NEO100 was well tolerated and correlated with improved survival when compared to historical controls, pointing to the possibility that this novel intranasalsal approach could become useful for the treatment of recurrent GBM.
Intranasal GM-CSF enhances efficacy of local ACNU delivery rendezvousing with TMZ plus irradiation in glioblastoma
Intranasal GM-CSF enhances the efficacy of the local delivery of ACNU rendezvousing with oral TMZ chemotherapy associated with significantly improved survival and quality of life in glioblastoma patients after surgery.
Intranasal Administration of Temozolomide Delayed the Development ofBrain Tumors Initiated by Human Glioma Stem-Like Cell in Nude Mice
The results demonstrate that the intranasal route should be further considered as an option for TMZ delivery into the brain to treat intrastriatal brain tumours, and consists of an easy, fast, and cost-less method to gain direct access to the brain.
WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.
How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases
Recent findings in molecular data on brain metastases are presented and future developments to facilitate drug penetration across the blood–brain barrier for the treatment of brain metastased patients, using physical methods or physiological transporters are discussed.


Intranasal delivery of biologics to the central nervous system.
Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
This review focuses on the current understanding of the mechanisms underlying intranasal delivery to the central nervous system involving the olfactory and trigeminal nerves, the vasculature, the cerebrospinal fluid, and the lymphatic system.
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.
Intranasal delivery of GRN163 readily bypassed the blood-brain barrier, exhibited favorable tumor uptake, and inhibited tumor growth, leading to a prolonged lifespan for treated rats compared to controls, and these data support further development of intranasAL delivery of tumor-specific therapeutic agents for brain tumor patients.
Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy.
The strategy to utilize the nose-brain direct transport can be applicable to a new therapeutic system not only for brain tumors but also for other central nervous system disorders such as neurodegenerative diseases.
Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol
Intranasal administration of the signal transduction inhibitor POH is a safe, noninvasive, and low-cost method and the regression of tumor size in some patients is suggestive of antitumor activity.
Transnasal delivery of anticancer drugs to the brain tumor : A new strategy for brain tumor chemotherapy
It was clarified that efficient chemotherapy of the brain tumor and the reduction of systemic side effects are enabled by nasal application of anticancer agents.